Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Anticancer Res ; 31(10): 3151-7, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21965721

ABSTRACT

BACKGROUND: The cyclin B1/CDC2 complex governs entry into mitosis by regulating the G(2)/M checkpoint, and it can be repressed by the tumor suppressor p53. We aimed to determine cyclin B1 expression in squamous cell carcinomas of the head and neck (SCCHN) and correlate it with p53 status and clinicopathological parameters. PATIENTS AND METHODS: Cyclin B1 and p53 protein expression was analyzed by immunohistochemistry, and p53 mutation analyses were performed. RESULTS: Cytoplasmic expression of cyclin B1 was found in all 26 SCCHN studied. In contrast, nuclear staining was seen in the basal layers of normal mucosa. A total of 46% of tumors showed high cyclin B1 expression. p53 was overexpressed in 53.8% of cases, and of these 79% carried a p53 gene mutation. High cyclin B1 expression significantly correlated with the high tumor grade, but not with gender, tumor size, nodal status, local tumor recurrence or p53 expression. CONCLUSION: Cyclin B1 is frequently overexpressed in SCCHN, and its high expression is significantly associated with a high tumor grade. These data suggest that cyclin B1 may serve as a potential prognostic biomarker in SCCHN.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Cyclin B1/metabolism , Head and Neck Neoplasms/metabolism , Tumor Suppressor Protein p53/metabolism , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Female , Head and Neck Neoplasms/pathology , Humans , Immunohistochemistry , Male , Middle Aged , Mutation/genetics , Squamous Cell Carcinoma of Head and Neck
2.
Am J Kidney Dis ; 25(3): 380-9, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7872315

ABSTRACT

Autoantibodies directed against neutrophil cytoplasmic antigens (ANCA) are valuable in the diagnosis of primary systemic vasculitis, and immunofluorescence studies suggest that changes in ANCA concentration reflect changes in disease activity. We used enzyme-linked immunosorbent assays to examine retrospectively the relationship between ANCA concentration and disease activity in 56 patients with systemic vasculitis. We included patients with Wegener's granulomatosis, microscopic polyangiitis, idiopathic rapidly progressive glomerulonephritis, and Churg-Strauss syndrome, and examined separately the initial treatment period (mean length of follow-up, 26 months) and long-term management (mean length of follow-up, 59 months). Levels of ANCA decreased during induction therapy with prednisolone and cyclophosphamide, with or without plasma exchange. During follow-up, 27 relapses were documented in 20 patients (10 with Wegener's granulomatosis, nine with microscopic polyangiitis, and one with Churg-Strauss syndrome), occurring between 4 and 183 months (mean, 62 months) after initial presentation. Patients in whom ANCA were detectable 1 year or more after treatment were at particular risk of clinical relapse. Proteinase 3-directed ANCA appeared to be associated with a higher rate of relapse (44% of patients relapsed) than myeloperoxidase-directed ANCA (13% of patients relapsed). Twenty-four of the 27 relapses occurred in the presence of detectable ANCA; in 21 of these, ANCA concentration was high or rising. The temporal relationship between changes in ANCA concentration and clinical relapse varied considerably between patients; in seven patients, ANCA remained at high levels for many months (range, 14 to 67 months) before eventual relapse. One patient showed high concentrations of ANCA over a period of 11 years without relapse. In five patients, increases in the ANCA level were not temporally associated with relapse (although four of these patients relapsed on other occasions.) We conclude that monitoring ANCA by enzyme-linked immunosorbent assays is of value in the long-term management of patients with Wegener's granulomatosis, microscopic polyangiitis, idiopathic rapidly progressive glomerulonephritis, and Churg-Strauss syndrome. Increases in ANCA and persistently high levels point to the risk of relapse and indicate the need for frequent clinical review and continuing maintenance immunosuppression. However, our results suggest that ANCA assays should always be used in conjunction with other indices of disease activity and should not be the sole basis for changing therapy.


Subject(s)
Autoantibodies/blood , Biomarkers/blood , Vasculitis/diagnosis , Antibodies, Antineutrophil Cytoplasmic , Cyclophosphamide/therapeutic use , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Male , Middle Aged , Plasma Exchange , Prednisolone/therapeutic use , Recurrence , Retrospective Studies , Risk Factors , Time Factors , Vasculitis/epidemiology , Vasculitis/immunology , Vasculitis/therapy
3.
Plant Cell Rep ; 15(1-2): 106-10, 1995 Jan.
Article in English | MEDLINE | ID: mdl-24185665

ABSTRACT

Protoplasts were isolated from leaf explants ofPassiflora edulis var.flavicarpa (the yellow passion fruit) and from cell suspensions of fivePassiflora species. Chemical fusion was performed using polyethylene glycol and the microcolonies obtained were transferred to growth medium to produce calli. Electrophoresis of soluble proteins and analysis of isoenzymes from calli produced from the fusion experiments were performed to select somatic hybrids. Specific polypeptide bands allowed the identification of somatic hybrids betweenP. edulis var.flavicarpa (+)P. alata, P. edulis var.flavicarpa (+)P. amethystina, P. edulis var.flavicarpa (+)P. cincinnata, P. edulis var.flavicarpa (+)P. giberti andP. edulis var.flavicarpa (+)P. coccinea. An average of 3 to 5% hybrid calli were obtained. With the exception of theP. edulis var.flavicarpa (+)P. coccinea, whole plants were recovered from all hybrids. These somatic hybrids showed 4n=36 chromosomes, which represents a further evidence of their hybridity.

4.
Cancer Invest ; 12(4): 403-5, 1994.
Article in English | MEDLINE | ID: mdl-8032961

ABSTRACT

Eighteen patients with either metastatic or locally advanced pancreatic carcinoma were treated with intravenous infusion of Pirarubicin 50 mg/m2/day every 3 weeks. Seventeen patients were evaluable for response. One had minor response, 5 had stable disease, and 11 had progression of disease. Hematological toxicity was moderate, leading to a dose reduction in only 1 patient; there was no clinical cardiac toxicity. We conclude that Pirarubicin used with this dosage and schedule has no activity in advanced pancreatic carcinoma.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Doxorubicin/analogs & derivatives , Pancreatic Neoplasms/drug therapy , Adult , Aged , Antibiotics, Antineoplastic/adverse effects , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Male , Middle Aged
5.
Adv Exp Med Biol ; 336: 303-4, 1993.
Article in English | MEDLINE | ID: mdl-8296622

ABSTRACT

Solid-phase immunoassays were used to examine the relationship between ANCA concentration and disease activity during follow-up of 63 patients with systemic vasculitis. ANCA levels fell with induction therapy. Relapses during long-term follow-up were generally associated with high or rising ANCA concentrations, although the temporal relationship between clinical relapse and changes in ANCA was variable.


Subject(s)
Autoantibodies/blood , Immunoglobulin G/blood , Vasculitis/blood , Vasculitis/drug therapy , Antibodies, Antineutrophil Cytoplasmic , Cyclophosphamide/therapeutic use , Humans , Prednisolone/therapeutic use , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...